Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Gilead Sciences, Inc. (GILD) witnessed a slew of price target hikes on Friday after the company raised its annual product ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...